Matches in SemOpenAlex for { <https://semopenalex.org/work/W41716981> ?p ?o ?g. }
Showing items 1 to 68 of
68
with 100 items per page.
- W41716981 endingPage "205" @default.
- W41716981 startingPage "195" @default.
- W41716981 abstract "Currently, there is not known tumoral marker for vesical carcinoma that would allow to distinguish when a surface tumour may become invasive.To analyze the functionality of a series of biological substances (CEA, CA 50, CA 19.9 and TPS) in vesical carcinoma.Between September 1992 and June 1994, a total of 385 biological specimens divided into two groups were analyzed. The first group comprised 271 serum samples from 81 control subjects and 190 patients with vesical carcinoma. The second group included 114 urothelial tissue samples (56 controls and 58 vesical carcinoma). Serum and tissue levels of CA, CA 50, CA 19.1 and TPS were determined in both groups by fluoroimmunoassay, RIA and IRMA, respectively. An statistical evaluation was done using Student's 't' and/or Mann-Whitney tests depending on whether data distribution adjusted to normal or not.Patients with vesical carcinoma, ana within this group those with infiltrant tumours, showed higher CEA serum levels. Also CEA tissue levels found in neoplastic vesical urothelium were higher than those in the control group (p < 0.05). Tissue levels were higher in infiltrant tumours. Higher TPS serum and tissue levels were found in the vesical tumours group. Same as with CEA, CA 50 also exhibited higher serum levels in the group with vesical Ca than in the controls (p < 0.01). Likewise, CA 50 tissue values were higher in the group with vesical Ca, more specifically in the infiltrant tumours group (p < 0.001). Statistically significant differences become apparent when the above values were compared to tissue samples from the control group (p < 0.001). On the other hand, serum CA 19.9 levels were lower in the vesical carcinoma group although tissue levels were higher in the vesical Ca group (p < 0.001).Transitional cell vesical carcinoma is a tumour that produces and secretes CEA, CA 50, CA 19.1 and TPS. CEA and CA 50 levels could be used as prognostic factors." @default.
- W41716981 created "2016-06-24" @default.
- W41716981 creator A5050119358 @default.
- W41716981 creator A5050377628 @default.
- W41716981 creator A5051716806 @default.
- W41716981 creator A5060317827 @default.
- W41716981 creator A5066413613 @default.
- W41716981 creator A5073165341 @default.
- W41716981 creator A5088180386 @default.
- W41716981 date "1997-03-01" @default.
- W41716981 modified "2023-09-23" @default.
- W41716981 title "[Advances regarding tumor markers in bladder cancer]." @default.
- W41716981 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/9324884" @default.
- W41716981 hasPublicationYear "1997" @default.
- W41716981 type Work @default.
- W41716981 sameAs 41716981 @default.
- W41716981 citedByCount "1" @default.
- W41716981 crossrefType "journal-article" @default.
- W41716981 hasAuthorship W41716981A5050119358 @default.
- W41716981 hasAuthorship W41716981A5050377628 @default.
- W41716981 hasAuthorship W41716981A5051716806 @default.
- W41716981 hasAuthorship W41716981A5060317827 @default.
- W41716981 hasAuthorship W41716981A5066413613 @default.
- W41716981 hasAuthorship W41716981A5073165341 @default.
- W41716981 hasAuthorship W41716981A5088180386 @default.
- W41716981 hasConcept C121608353 @default.
- W41716981 hasConcept C126322002 @default.
- W41716981 hasConcept C126894567 @default.
- W41716981 hasConcept C142724271 @default.
- W41716981 hasConcept C2777540882 @default.
- W41716981 hasConcept C2777546739 @default.
- W41716981 hasConcept C2777661416 @default.
- W41716981 hasConcept C2779762690 @default.
- W41716981 hasConcept C2780352672 @default.
- W41716981 hasConcept C71924100 @default.
- W41716981 hasConcept C90924648 @default.
- W41716981 hasConceptScore W41716981C121608353 @default.
- W41716981 hasConceptScore W41716981C126322002 @default.
- W41716981 hasConceptScore W41716981C126894567 @default.
- W41716981 hasConceptScore W41716981C142724271 @default.
- W41716981 hasConceptScore W41716981C2777540882 @default.
- W41716981 hasConceptScore W41716981C2777546739 @default.
- W41716981 hasConceptScore W41716981C2777661416 @default.
- W41716981 hasConceptScore W41716981C2779762690 @default.
- W41716981 hasConceptScore W41716981C2780352672 @default.
- W41716981 hasConceptScore W41716981C71924100 @default.
- W41716981 hasConceptScore W41716981C90924648 @default.
- W41716981 hasIssue "3" @default.
- W41716981 hasLocation W417169811 @default.
- W41716981 hasOpenAccess W41716981 @default.
- W41716981 hasPrimaryLocation W417169811 @default.
- W41716981 hasRelatedWork W2016391185 @default.
- W41716981 hasRelatedWork W2054585878 @default.
- W41716981 hasRelatedWork W2059413776 @default.
- W41716981 hasRelatedWork W2136751493 @default.
- W41716981 hasRelatedWork W2163114420 @default.
- W41716981 hasRelatedWork W2404158966 @default.
- W41716981 hasRelatedWork W2412441135 @default.
- W41716981 hasRelatedWork W24833777 @default.
- W41716981 hasRelatedWork W3128807963 @default.
- W41716981 hasRelatedWork W3181988015 @default.
- W41716981 hasVolume "21" @default.
- W41716981 isParatext "false" @default.
- W41716981 isRetracted "false" @default.
- W41716981 magId "41716981" @default.
- W41716981 workType "article" @default.